Karoline V. Gleixner

3.8k total citations
89 papers, 2.4k citations indexed

About

Karoline V. Gleixner is a scholar working on Hematology, Immunology and Molecular Biology. According to data from OpenAlex, Karoline V. Gleixner has authored 89 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 42 papers in Immunology and 28 papers in Molecular Biology. Recurrent topics in Karoline V. Gleixner's work include Mast cells and histamine (41 papers), Chronic Myeloid Leukemia Treatments (35 papers) and Eosinophilic Disorders and Syndromes (21 papers). Karoline V. Gleixner is often cited by papers focused on Mast cells and histamine (41 papers), Chronic Myeloid Leukemia Treatments (35 papers) and Eosinophilic Disorders and Syndromes (21 papers). Karoline V. Gleixner collaborates with scholars based in Austria, United States and Germany. Karoline V. Gleixner's co-authors include Peter Valent, Wolfgang R. Sperr, Matthias Mayerhofer, Winfried F. Pickl, Christian Sillaber, Sabine Cerny‐Reiterer, Alexander Gruze, Karl J. Aichberger, Harald Herrmann and Emir Hadzijusufovic and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Karoline V. Gleixner

87 papers receiving 2.4k citations

Peers

Countries citing papers authored by Karoline V. Gleixner

Since Specialization

Citations

This map shows the geographic impact of Karoline V. Gleixner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karoline V. Gleixner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karoline V. Gleixner more than expected).

Fields of papers citing papers by Karoline V. Gleixner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karoline V. Gleixner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karoline V. Gleixner. The network helps show where Karoline V. Gleixner may publish in the future.

Co-authorship network of co-authors of Karoline V. Gleixner

This figure shows the co-authorship network connecting the top 25 collaborators of Karoline V. Gleixner. A scholar is included among the top collaborators of Karoline V. Gleixner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karoline V. Gleixner. Karoline V. Gleixner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impaired hemostatic and immune functions of platelets after acute thrombocytopenia 2024 ·Journal of Thrombosis and Haemostasis ·(unknown), Waltraud C. Schrottmaier, (unknown), Hubert Hackl, (unknown), (unknown), Sarah Beck, Johanna Gebhart, Karoline V. Gleixner, Wolfgang R. Sperr, Alice Assinger	1
2	BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL 2024 ·American Journal of Hematology ·Karin Bauer, Alexander W. Hauswirth, Karoline V. Gleixner, Georg Greiner, J. Thaler, Peter Bettelheim, (unknown), Elisabeth Koller, Gregor Hoermann, Philipp B. Staber, Wolfgang R. Sperr, Felix Keil, Peter Valent	15
3	Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts 2023 ·International Journal of Molecular Sciences ·Peter Valent, Cem Akin, Michel Arock, Karoline V. Gleixner, Hildegard Greinix, Olivier Hermine, Hans‐Peter Horny, (unknown), Alberto Órfão, Werner Rabitsch, Andreas Reiter, Axel Schulenburg, Karl Sotlar, Wolfgang R. Sperr, Celalettin Üstün	1
4	N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia 2023 ·American Journal of Hematology ·(unknown), Georg Greiner, Rodrig Marculescu, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knoebl, Ulrich Jäger, Alexander W. Hauswirth, Ilse Schwarzinger, Renate Thalhammer, Michael Kundi, Gregor Hoermann, Gerlinde Mitterbauer‐Hohendanner, Peter Valent, Wolfgang R. Sperr	5
5	Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives 2023 ·Expert Review of Hematology ·Peter Valent, Irina Sadovnik, Barbara Peter, (unknown), Axel Schulenburg, Emir Hadzijusufovic, Michael Willmann, Thomas Rülicke, Harald Herrmann, Werner Rabitsch, Heidrun Karlic, Karoline V. Gleixner, Wolfgang R. Sperr, Gregor Hoermann, Maik Dahlhoff, Michael Pfeilstöcker, Felix Keil, Thomas Lion, Thomas W. Grunt	0
6	Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations 2021 ·American Journal of Cancer Research ·Karoline V. Gleixner, (unknown), Daniela Berger, (unknown), Gabriele Stefanzl, Irina Sadovnik, (unknown), Gregor Eisenwort, Mathias Schneeweiss‐Gleixner, Konstantin Byrgazov, Wolfgang R. Sperr, Jiřı́ Mayer, Thomas Lion, Peter Valent	28
7	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML 2019 ·EBioMedicine ·Mathias Schneeweiss‐Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, (unknown), Susanne Herndlhofer, Sandra Preuner, (unknown), (unknown), Nadine Witzeneder, Georg Greiner, Gregor Hoermann, Wolfgang R. Sperr, Thomas Lion, Michael W. Deininger, Peter Valent, Karoline V. Gleixner	13
8	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis 2018 ·Haematologica ·Michel Arock, (unknown), Gregor Hoermann, (unknown), Cem Akin, Barbara Peter, Karoline V. Gleixner, Karin Hartmann, Joseph H. Butterfield, Dean D. Metcalfe, Peter Valent	13
9	Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V 2013 ·Haematologica ·Karoline V. Gleixner, Barbara Peter, K. Blatt, (unknown), Andreas Reiter, Deepti Radia, Emir Hadzijusufovic, Peter Valent	37
10	The Hsp32 Inhibitors SMA-ZnPP and PEG-ZnPP Exert Major Growth-Inhibitory Effects on D34+/CD38+ and CD34+/CD38- AML Progenitor Cells 2012 ·Current Cancer Drug Targets ·Harald Herrmann, Michael Kneidinger, Sabine Cerny‐Reiterer, Thomas Rülicke, Michael Willmann, Karoline V. Gleixner, K. Blatt, (unknown), Barbara Peter, Puchit Samorapoompichit, Winfried F. Pickl, Gahininath Y. Bharate, Matthias Mayerhofer, Wolfgang R. Sperr, Hiroshi Maeda, Peter Valent	26
11	Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536 2011 ·Haematologica ·Barbara Peter, Karoline V. Gleixner, Sabine Cerny‐Reiterer, Harald Herrmann, Vibeke Winter, Emir Hadzijusufovic, (unknown), (unknown), Irina Mirkina, H.-P. Horny, Winfried F. Pickl, Leonhard Müllauer, Michael Willmann, Peter Valent	12
12	Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536 2010 ·Cancer Research ·Karoline V. Gleixner, (unknown), Barbara Peter, Alexander Gruze, (unknown), Emir Hadzijusufovic, Sabine Cerny‐Reiterer, Matthias Mayerhofer, Winfried F. Pickl, Christian Sillaber, Peter Valent	74
13	KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406) 2010 ·Experimental Hematology ·Barbara Peter, Emir Hadzijusufovic, Katharina Blatt, Karoline V. Gleixner, Winfried F. Pickl, Tuddow Thaiwong, Vilma Yuzbasiyan‐Gurkan, Michael Willmann, Peter Valent	10
14	In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V 2010 ·Experimental Hematology ·Alexandra Böhm, Karoline Sonneck, Karoline V. Gleixner, (unknown), Winfried F. Pickl, Katharina Blatt, Barbara Peter, Harald Herrmann, G. Schernthaner, Hubert Pehamberger, Werner Rabitsch, Wolfgang R. Sperr, Peter Valent	36
15	Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis 2009 ·American Journal Of Pathology ·Christian Baumgärtner, Sabine Cerny‐Reiterer, Karoline Sonneck, Matthias Mayerhofer, Karoline V. Gleixner, Richard R. Fritz, Marc A. Kerenyi, Cédric Boudot, Fabrice Gouilleux, Jan‐Wilhelm Kornfeld, Christian Sillaber, Richard Moriggl, Peter Valent	60
16	Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation 2009 ·Veterinary Immunology and Immunopathology ·Emir Hadzijusufovic, Barbara Peter, (unknown), Christian Baumgärtner, Karoline V. Gleixner, Alexander Gruze, Tuddow Thaiwong, Winfried F. Pickl, Vilma Yuzbasiyan‐Gurkan, Michael Willmann, Peter Valent	15
17	Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells 2009 ·European Journal of Clinical Investigation ·Alexandra Böhm, Karl J. Aichberger, Matthias Mayerhofer, Harald Herrmann, Stefan Florian, Maria Theresa Krauth, Sophia Derdak, Puchit Samorapoompichit, Karoline Sonneck, Anja Vales, Karoline V. Gleixner, Winfried F. Pickl, Wolfgang R. Sperr, Peter Valent	22
18	Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens 2008 ·The Journal of Immunology ·Matthias Mayerhofer, Karoline V. Gleixner, Andrea Hoelbl‐Kovacic, Stefan Florian, Gregor Hoermann, Karl J. Aichberger, Martin Bilban, Harald Esterbauer, Maria‐Theresa Krauth, Wolfgang R. Sperr, Jack Longley, Róbert Královics, Richard Moriggl, Jacques Zappulla, Roland Liblau, Ilse Schwarzinger, Veronika Sexl, Christian Sillaber, Peter Valent	58
19	Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRα 2008 ·Experimental Hematology ·Christian Baumgärtner, Karoline V. Gleixner, Barbara Peter, (unknown), Alexander Gruze, Lily L. Remsing Rix, Keiryn L. Bennett, Puchit Samorapoompichit, Francis Y. Lee, Winfried F. Pickl, Harald Esterbauer, Christian Sillaber, Giulio Superti‐Furga, Peter Valent	22
20	Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia 2006 ·Leukemia & lymphoma ·Karoline Sonneck, Stefan Florian, Alexandra Böhm, Maria‐Theresa Krauth, Rudin Kondo, Alexander W. Hauswirth, Karoline V. Gleixner, Karl J. Aichberger, Sophia Derdak, Winfried F. Pickl, Wolfgang R. Sperr, Lawrence B. Schwartz, Peter Valent	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact